ARWR
Price
$41.14
Change
-$0.28 (-0.68%)
Updated
Nov 13 closing price
Capitalization
5.69B
11 days until earnings call
Intraday BUY SELL Signals
CUE
Price
$0.62
Change
-$0.05 (-7.46%)
Updated
Nov 13 closing price
Capitalization
46.91M
130 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARWR vs CUE

Header iconARWR vs CUE Comparison
Open Charts ARWR vs CUEBanner chart's image
Arrowhead Pharmaceuticals
Price$41.14
Change-$0.28 (-0.68%)
Volume$1.54M
Capitalization5.69B
Cue Biopharma
Price$0.62
Change-$0.05 (-7.46%)
Volume$3.44M
Capitalization46.91M
ARWR vs CUE Comparison Chart in %
View a ticker or compare two or three
VS
ARWR vs. CUE commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Hold and CUE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (ARWR: $41.42 vs. CUE: $0.67)
Brand notoriety: ARWR: Notable vs. CUE: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 97% vs. CUE: 67%
Market capitalization -- ARWR: $5.69B vs. CUE: $46.91M
ARWR [@Biotechnology] is valued at $5.69B. CUE’s [@Biotechnology] market capitalization is $46.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileCUE’s FA Score has 1 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • CUE’s FA Score: 1 green, 4 red.
According to our system of comparison, ARWR is a better buy in the long-term than CUE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 3 TA indicator(s) are bullish while CUE’s TA Score has 3 bullish TA indicator(s).

  • ARWR’s TA Score: 3 bullish, 5 bearish.
  • CUE’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, ARWR is a better buy in the short-term than CUE.

Price Growth

ARWR (@Biotechnology) experienced а +2.75% price change this week, while CUE (@Biotechnology) price change was -8.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

ARWR is expected to report earnings on Nov 25, 2025.

CUE is expected to report earnings on Mar 24, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($5.69B) has a higher market cap than CUE($46.9M). ARWR YTD gains are higher at: 120.319 vs. CUE (-38.752). CUE has higher annual earnings (EBITDA): -36.07M vs. ARWR (-52.51M). ARWR has more cash in the bank: 900M vs. CUE (27.5M). CUE has less debt than ARWR: CUE (7.63M) vs ARWR (353M). ARWR has higher revenues than CUE: ARWR (573M) vs CUE (8.29M).
ARWRCUEARWR / CUE
Capitalization5.69B46.9M12,128%
EBITDA-52.51M-36.07M146%
Gain YTD120.319-38.752-310%
P/E RatioN/AN/A-
Revenue573M8.29M6,915%
Total Cash900M27.5M3,273%
Total Debt353M7.63M4,624%
FUNDAMENTALS RATINGS
ARWR vs CUE: Fundamental Ratings
ARWR
CUE
OUTLOOK RATING
1..100
7364
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
3584
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
1n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CUE's Valuation (26) in the Biotechnology industry is significantly better than the same rating for ARWR (100). This means that CUE’s stock grew significantly faster than ARWR’s over the last 12 months.

CUE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARWR (100). This means that CUE’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's SMR Rating (97) in the Biotechnology industry is in the same range as CUE (99). This means that ARWR’s stock grew similarly to CUE’s over the last 12 months.

ARWR's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for CUE (84). This means that ARWR’s stock grew somewhat faster than CUE’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for CUE (100). This means that ARWR’s stock grew significantly faster than CUE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRCUE
RSI
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 9 days ago
79%
Declines
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signal:
Gain/Loss:
CUE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MEDIF0.05N/A
+0.13%
Medipharm Labs Corporation
SKSJF6.51N/A
N/A
Shinko Shoji Co Ltd.
ZEOOF9.35N/A
N/A
Zeon Corp.
SFOSF3.30N/A
N/A
Shanghai Fosun Pharmaceutical Group Co Ltd
NEWEN100.04-24.93
-19.95%
New England Power Co.

CUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, CUE has been loosely correlated with SGMT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CUE jumps, then SGMT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CUE
1D Price
Change %
CUE100%
-2.25%
SGMT - CUE
43%
Loosely correlated
+3.76%
CRBU - CUE
41%
Loosely correlated
+0.89%
ABCL - CUE
39%
Loosely correlated
-1.00%
ARWR - CUE
37%
Loosely correlated
-0.19%
IMNM - CUE
37%
Loosely correlated
-0.51%
More